Results 71 to 80 of about 811,174 (190)

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli   +4 more
wiley   +1 more source

Candidate compounds from the design of covalent Bruton's tyrosine kinase (BTK) inhibitors via focused deep generative modeling

open access: yes, 2022
A total of 1491 candidate inhibitors for covalent inhibition of BTK are deposited as SMILES strings together with 34 known covalent BTK inhibitors used to guide generative computational design.
Atsushi Yoshimori   +2 more
core   +1 more source

New anti‐inflammatory and remodelling drugs for unmet clinical needs in severe asthma and chronic obstructive pulmonary disease (COPD)

open access: yesBritish Journal of Pharmacology, EarlyView.
There have been several step‐changes in asthma therapy, with the first being the use of inhaled short‐acting β2‐agonists as bronchodilators and the introduction of inhaled corticosteroids (ICS) to reduce airway inflammation. The next revolution was the advent of inhaled combinations of long‐acting bronchodilators together with inhaled corticosteroids ...
Ian M. Adcock
wiley   +1 more source

Machine Learning‐Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma

open access: yesCancer Science, EarlyView.
An immune‐related 12‐gene signature developed through integrative machine learning stratified overall survival across multiple myeloma cohorts and remained independently associated with outcome. Single‐cell, somatic mutation, and transcriptome‐based drug‐response analyses further linked the signature to multicellular bone marrow context, distinct ...
Kai Wang   +10 more
wiley   +1 more source

BTK Inhibitor Ibrutinib Reduces Bispecific Antibody‐Related CRS Without Undermining the Anti‐Tumor Efficacy

open access: yesCancer Science, EarlyView.
BTK inhibition reprograms macrophages to suppress IL‐6/IL‐8/IL‐10‐driven CRS without compromising BsAb efficacy. ABSTRACT Bispecific antibodies (BsAbs) have shown marked efficacy in relapsed or refractory (R/R) B‐cell non‐Hodgkin lymphoma (B‐NHL). However, their clinical utility is constrained by cytokine release syndrome (CRS).
Jiaowu Cao   +8 more
wiley   +1 more source

Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors

open access: yes, 2017
Introduction: Btk is a tyrosine kinase dysregulated in several B-cell malignancies and autoimmune diseases, and this has given rise to a search for Btk inhibitors. Nevertheless, only one Btk inhibitor, ibrutinib, has been approved to date, although other
Rosario Amato   +13 more
core   +1 more source

T‐Cell Response After SARS‐CoV‐2 Vaccination in Patients With Hematological Malignancy

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Patients with hematologic malignancies (HM) often mount poor humoral responses to SARS‐CoV‐2 vaccination due to their immunocompromised status. Protection against severe COVID‐19 is strongly related to cellular immunity, yet vaccine‐induced T‐cell responses remain incompletely characterized.
L. S. Boerenkamp   +7 more
wiley   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

open access: yesThe FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin   +2 more
wiley   +1 more source

AustrAIHANZ – consensus guidelines on the investigation and management of autoimmune haemolytic anaemia in Australia and New Zealand

open access: yesInternal Medicine Journal, EarlyView.
Abstract Autoimmune haemolytic anaemia is a rare immune‐mediated disorder leading to accelerated red cell destruction and anaemia. There is considerable clinical heterogeneity, with some patients barely requiring intervention, while others experience fulminant haemolysis and experience mortality rates as high as 30% with severe anaemia and end‐organ ...
Philip Choi   +9 more
wiley   +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy